Spots Global Cancer Trial Database for oprozomib
Every month we try and update this database with for oprozomib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01832727 | Multiple Myelom... | Oprozomib Dexamethasone | 18 Years - | Amgen | |
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors | NCT01129349 | Solid Tumors | Oprozomib | 18 Years - | Amgen | |
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | NCT01881789 | Multiple Myelom... | Oprozomib Lenalidomide Dexamethasone Cyclophosphamid... | 18 Years - | Amgen | |
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | NCT02227914 | Advanced Hepato... | Oprozomib Sorafenib | 18 Years - | Amgen | |
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | NCT02227914 | Advanced Hepato... | Oprozomib Sorafenib | 18 Years - | Amgen | |
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors | NCT01129349 | Solid Tumors | Oprozomib | 18 Years - | Amgen | |
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | NCT01881789 | Multiple Myelom... | Oprozomib Lenalidomide Dexamethasone Cyclophosphamid... | 18 Years - | Amgen | |
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies | NCT02244112 | Advanced Non-Ce... | Oprozomib Midazolam | 18 Years - | Amgen | |
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | NCT01416428 | Multiple Myelom... Waldenstrom Mac... | oprozomib | 18 Years - | Amgen |